Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - Hypertension
 More »

  • Top 20 Best-Selling Drugs Approved and Launched During 2012
    in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidemia, type 2 diabetes), in addition to diet and exercise Date of FDA ...
    4-4-2013
  • Affymax Reels as Omontys Linked to Five Deaths
    ... were diarrhea, vomiting, high blood pressure (hypertension), and joint, back, leg, or arm pain (arthralgia)," FDA said in its press release announcing approval of the Affymax drug. ...
    2-26-2013
  • En Bloc Analysis of Epigenetic Publications
    ... expected. Figure 3B hints that research focus on other diseases such as hypertension, neurological diseases, obesity, and prognostic or predictive biomarkers may be accelerating. ...
    2-1-2013
  • Pluristem Sets Up Shop in New Manufacturing Facility
    These include critical limb ischemia, intermittent claudication, adjuvant hip replacement surgery, muscle injuries, pulmonary hypertension and a number of other disorders. ...
    1-30-2013
  • Drug Repurposing Rekindles Promise
    ... After the first beta-blocker, propranolol (Inderal), was discovered by J.W. Black, M.D., in the mid-1960s, beta-blockers found widespread use for treating hypertension. Anecdotal ...
    1-25-2013
  • Peptide Development Goes Virtual
    ... of osteoporosis, and the reversal of the inflammatory component of the metabolic syndrome (insulin resistance, diabetes, hypertension, atherosclerosis) resulting from obesity. ...
    1-15-2013
  • Hearing Better Through Chemistry
    It is the third most prevalent chronic condition in older Americans after hypertension and arthritis. Age-related hearing loss (ARHL) is a leading cause of adult hearing handicaps ...
    12-19-2012
  • Tarix Licenses Unigene's Peptelligence for Peptide Drug
    TXA127 has been granted orphan drug status by FDA for pulmonary arterial hypertension, to enhance engraftment in patients receiving a stem cell transplant, and for myelodysplastic ...
    11-27-2012
  • XOMA Combination Drug Shows Phase III Promise
    amlodipine for the treatment of hypertension) disclosed by XOMA, the company said ... its impact in treating essential hypertension and stable coronary artery disease. ...
    11-21-2012
  • BioCat and Alpco Sign Distribution Agreement
    In March of this year, Alpco and Detroit R&D forged a distribution partnership by which Detroit R&D would use Alpco's immunoassay market presence as a channel for its hypertension ...
    11-19-2012
  • The 10 Most Well-Connected People in Biotech
    ... of the Section on Endocrinology, Metabolism and Hypertension, 1987-1991 William K. Warren Professor for Diabetes Studies, 1989-1991 Washington University School of Medicine in St. ...
    10-29-2012
  • Boehringer Settles Fraud Charges for $95M
    to prescribe the four drugs-the stroke-prevention drug Aggrenox, the chronic obstructive pulmonary disease (COPD) drugs Atrovent and Combivent, and the hypertension drug Micardis. ...
    10-26-2012
  • More Good News for Bayer
    (Bay 63-2521) in patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or with persistent/recurrent pulmonary hypertension (PH) following surgery. ...
    10-24-2012
  • Bayer Drug Succeeds in Phase III PAH Trial
    as a treatment for pulmonary arterial hypertension (PAH) in treatment-naïve patients and ... for other types of pulmonary hypertension, including chronic thromboembolic ...
    10-22-2012
  • Merck & Co. Licenses Cardiovascular Candidates from Theravance
    small molecule therapeutics against a candidate hypertension and heart failure target. ... therapeutics against a candidate hypertension and heart failure target. Merck & Co. ...
    10-16-2012
  • More »

    Journal Articles

  • A Telehealth Strategy for Increasing Adherence in the Treatment...
    Marcos Vinicius Ribeiro dos Santos, Magdala de Araújo Novaes, Dinaldo Cavalcanti de Oliveira
    Telemedicine and e-Health
    A Telehealth Strategy for Increasing Adherence in the Treatment of Hypertension in Primary ... This strategy aimed to increase the adherence to the treatment of hypertension. METHODS: ...
  • Anthropometric Measurements and Diabetes Mellitus: Clues to the...
    Harold E. Bays, Kathleen M. Fox, Susan Grandy
    Metabolic Syndrome and Related Disorders
    visceral adipose tissue (VAT) is "pathogenic" through adverse endocrine and immune contributions to metabolic diseases such as diabetes mellitus, hypertension, and dyslipidemia. ...
  • Hypertensive Treatment in Patients With Metabolic Syndrome
    David Siegel, Arthur L.M. Swislocki
    Metabolic Syndrome and Related Disorders
    Hypertensive Treatment in Patients With Metabolic Syndrome Metabolic Syndrome and Related Disorders The prevalence of obesity, hypertension, and type 2 diabetes mellitus-in other ...
  • Antihypertensive Treatment, High Triglycerides, and Low High...
    Poul Suadicani, Hans Ole Hein, Finn Gyntelberg
    Metabolic Syndrome and Related Disorders
    The main outcome was IHD mortality. Results: Men treated for hypertension had a two-fold higher cumulative incidence of IHD mortality during the follow up compared to other men ...

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Genome Sequencing and Patient Autonomy

Do you think ACMG’s recent recommendations for reporting incidental clinical sequencing results undermine patient autonomy?

Suggest a Poll